Open Journal of Obstetrics and Gynecology

Volume 3, Issue 2 (March 2013)

ISSN Print: 2160-8792   ISSN Online: 2160-8806

Google-based Impact Factor: 0.37  Citations  h5-index & Ranking

Single versus combination therapy in acute tocolysis: A prospective randomized controlled trial

HTML  XML Download Download as PDF (Size: 420KB)  PP. 249-256  
DOI: 10.4236/ojog.2013.32047    5,403 Downloads   8,813 Views  Citations

ABSTRACT

This is a prospective controlled randomized trial conducted in 92 women with singleton pregnancies in preterm labor. The tocolytic efficacy and safety of combination atosiban and nifedipine was compared with that of the single agent, atosiban. Both lines of intervention was administered for 48 hours. Progression of labor was assessed by the frequency of uterine contractions and cervical changes. For statistical purpose, intent-to-treat (ITT) analysis was used throughout. Efficacy, as determined by the proportion of women in each group who did not deliver after therapy initiation, was comparable with no significant differences, at 48 hrs (91.5% vs. 91.1%) and at 7 days (90.7% vs. 85.7%) for the atosiban and the combination groups respectively. Safety was assessed by the numbers of adverse events. Maternal side effects were reported more in the combination group (34% vs. 64%; P = 0.006). Perinatal outcomes were similar between the groups. We conclude that the addition of nifedipine did not substantially improve the clinical outcomes beyond that were achieved with atosiban alone. Moreover, it has increased maternal side effects. Future research could focus on combination of other tocolytics.

Share and Cite:

Al-Omari, W. , Begam, M. , Khan, F. , Khudhair, I. and Nagelkerke, N. (2013) Single versus combination therapy in acute tocolysis: A prospective randomized controlled trial. Open Journal of Obstetrics and Gynecology, 3, 249-256. doi: 10.4236/ojog.2013.32047.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.